Skip to content

Comparison of continuous versus intermittent administration of insulin for the treatment of diabetic ketoacidosis in children

Rapid acting intermittent subcutaneous insulin versus continuous intravenous infusion of regular insulin in the management of DKA in children - A non-inferiority trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020687
Enrollment
56
Registered
2019-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E101- Type 1 diabetes mellitus with ketoacidosis

Interventions

Intervention1: Lispro group: Subcutaneous (SC) rapid-acting analog-Lispro will be initiated at a dose of 0.15 U/kg every 2 hours, the first dose being administered one hour after the initiation of flu

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children aged 1 month to 12 years (completed), admitted in the department of Pediatrics, JIPMER, with the diagnosis of DKA will be included. The diagnosis of DKA will be based on Clinical Practice Consensus Guidelines 2018 by ISPAD (International Society for Pediatric and Adolescent Diabetes)

Exclusion criteria

Exclusion criteria: 1. Children with complicated DKA requiring intubation 2. Children with symptomatic cerebral edema with raised ICP requiring osmotic agents (mannitol, 3% saline) 3. Children in shock requiring vasoactive agents 4. Children with diagnosed inborn error of metabolism

Design outcomes

Primary

MeasureTime frame
To compare the time to resolution of DKA in children (1 month- 12yrs) managed with continuous intravenous regular insulin infusion (group1) versus rapid acting intermittent subcutaneous insulin (group 2)Timepoint: Resolution of DKA(Definition as per ISPAD guidelines)

Secondary

MeasureTime frame
Duration of therapy until glucose is 250 mg/dl (hours)Timepoint: Until glucose is less than 250 mg/dl;Amount of Insulin administered until glucose is less than 250 mg/dl (units)Timepoint: Until glucose is less than 250 mg/dl;Amount of Insulin administered until resolution of DKA (units)Timepoint: Until resolution of DKA;Duration of PICU stay (days)Timepoint: until discharge from PICU;Duration of hospital stay (days)Timepoint: Until discharge from hospital;Hypoglycemic episodesTimepoint: Until resolution of DKA;Adverse events other than hypoglycemic episodes (Cerebral edema, AKI, death)Timepoint: Until resolution of DKA;Proportion of all cause in hospital mortalityTimepoint: Until discharge from hospital

Countries

India

Contacts

Public ContactR SANTHOSH KUMAR

JIPMER

narayanan.p@jipmer.edu.in9443458850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026